Nanoform and Takeda Showcase Advances in Biologic Drug Delivery at DDF Summit
At the 15th Drug Delivery & Formulation Summit in Boston, Nanoform unveiled proof‑of‑concept data demonstrating new approaches to biologic drug delivery.
Nanoparticle company, Nanoform, has unveiled the results from two proof-of-concept studies in collaboration with Takeda at the 15th American Drug Delivery & Formulation Summit (DDF) in Boston. The new data demonstrates advances in the delivery of biologic medicine using Nanoform’s patented technology platforms, addressing patient convenience and therapeutic impact through alternative routes of administration and higher dosing concentrations (1).
The first study involved creating formulations of biologic drugs at high concentration for subcutaneous injection — exceeding the typical acceptable limit of 200 mg/mL at which the high viscosity makes it challenging to inject. The research demonstrated that Nanoform’s methods can maintain high protein concentrations in suspension formulations that remain suitable for subcutaneous delivery, as confirmed by syringeability testing. This advance could benefit patients requiring frequent therapies, such as monoclonal antibodies by reducing injection volumes and potentially allowing self-administration outside of clinical settings.
The second study explored new ways of delivering nanoformed Alpha-1 antitrypsin (A1AT) to target Alpha-1 antitrypsin (AAT) deficiency — a hereditary disorder that often leads to lung diseases like emphysema. Current treatment for AAT deficiency typically involves weekly intravenous infusions of plasma-derived AAT, a regimen that many patients find inconvenient and burdensome. Seeking an alternative, Nanoform and Takeda investigated a dry powder inhalation therapy developed with Nanoform’s solidification technology. Initial findings indicate that the inhaled approach is feasible and may provide a more convenient, less invasive option than regular intravenous infusions, aligning with growing patient demand for flexible and non-invasive treatment solutions.
Additionally, Nanoform presented data on the development of a highly concentrated, non-aqueous subcutaneous formulation of trastuzumab — a monoclonal antibody widely used in cancer therapy — using its Bio platform. Subcutaneous formulation of trastuzumab has previously proven to be a valid and non-inferior alternative to intravenous delivery (2), suggesting this new nanoformed approach may further optimize ease of use and stability.
Nanoform’s leadership, including the Vice President of Business Development, U.S., Dr. Christopher P. Worrall, delivered further insights at the Boston event, emphasizing the company’s focus on bringing innovative, patient-centric drug products to market to demonstrate the progress of the ongoing collaboration with Takeda in the pursuit of better medicine performance, reduced clinical attrition, and enhanced patient outcomes.
References
Nanoform. Results of Nanoform Collaborative Study to be Presented at US Drug Delivery & Formulation (DDF) Summit. Press Release, Sep. 11, 2025.
Ismael, G.; Hegg, R.; Muehlbauer, S.; et al. Subcutaneous Versus Intravenous Administration of (Neo)Adjuvant Trastuzumab in Patients with HER2-Positive, Clinical Stage I–III Breast Cancer (HannaH Study): a Phase III, Open-label, Multicentre, Randomised Trial. The Lancet Oncology, 2012, 13 (9),869-878.